07:00 , Apr 16, 2015 |  BC Innovations  |  Finance

Public-Private Partnership Roundup

PPP activity in 1Q15 picked up where it left off at the end of last year, with 54 new partnerships disclosed, and big pharmas or biotechs accounting for 20 of those collaborations. AstraZeneca plc led...
07:00 , Oct 2, 2014 |  BC Innovations  |  Cover Story

NAMPT neuroprotection

Google Inc.-backed antiaging play Calico LLC has in-licensed its first molecules-inhibitors of neurodegeneration-following findings from The University of Texas Southwestern Medical Center and The University of Iowa that the compounds protect mice from traumatic brain...
07:00 , Sep 15, 2014 |  BC Week In Review  |  Company News

2M BioTech, Calico deal

2M BioTech granted Calico exclusive, worldwide rights to develop and commercialize a portfolio of modulators of nicotinamide phosphoribosyl transferase ( NamPRT; NAMPT). The deal includes 2M's preclinical P7C3 program, which has been focused...
02:40 , Sep 12, 2014 |  BC Extra  |  Company News

Calico gains P7C3 neurodegeneration program

2M BioTech L.P. (Dallas, Texas) granted Calico LLC (South San Francisco, Calif.) exclusive, worldwide rights to develop and commercialize a portfolio of modulators of nicotinamide phosphoribosyl transferase ( NamPRT; NAMPT). The deal includes 2M's preclinical...
07:00 , Oct 11, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Amyotrophic lateral sclerosis (ALS); Parkinson's disease (PD) Superoxide dismutase 1 (SOD1) Mouse and worm studies suggest a...